A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the CNS Effects of Single and Multiple Doses of CST-101, CST-103, and CST-109 in Healthy Subjects and Patients with Parkinson's Disease
Latest Information Update: 11 Aug 2021
At a glance
- Drugs Clenbuterol (Primary) ; CST 101 (Primary) ; CST-109 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms CHDR1915
- Sponsors CuraSen Therapeutics
- 11 Aug 2021 New trial record